Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 4/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | LMNA | P02545 | 4/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | HTT | P42858 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.47 |
| ▸ | ABAT | P80404 | 1/20 | 0.43 |
| ▸ | MTOR | P42345 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23328731 | 0.86 | MEN1 (0.61) | MEN1KMT2ALMNAHTTMAPT | |
| SCHEMBL25840843 | 0.85 | SMN1; SMN2 (0.51) | MEN1KMT2ASMN1; SMN2HTTMAPT | |
| SCHEMBL1258488 | 0.83 | ABAT (0.64) | MEN1KMT2ALMNASMN1; SMN2HTT | |
| SCHEMBL4396949 | 0.82 | KMT2A (0.64) | CDK1MEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL1433633 | 0.81 | IDH1 (0.47) | MEN1KMT2ALMNAHTTMAPT | |
| SCHEMBL23328373 | 0.81 | ABAT (0.66) | CDK1MEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL10453740 | 0.80 | IDO1 (0.49) | MEN1KMT2ALMNAHTTMAPT | |
| SCHEMBL5803117 | 0.79 | PTPRC (0.54) | SMN1; SMN2EPHX2TRPV1 | |
| SCHEMBL1138925 | 0.76 | EPHX2 (0.59) | MEN1KMT2ALMNAHTTMAPT | |
| SCHEMBL14386106 | 0.76 | LMNA (0.72) | CDK1MEN1KMT2ALMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11701333-B2 | Antibacterial compounds | Kent Innovation & Enterprise (GB) | 2023-07-18 | — | — | US | disclosed |
| US-20210128501-A1 | ANTIBACTERIAL COMPOUNDS | KENT INNOVATION & ENTERPRISE, UNIVERSITY OF KENT (GB) | 2021-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11701333-B2 | Antibacterial compounds | ARF1, ARL1, TLR1 | CDK1 1597/4885MEN1 1300/4885KMT2A 2533/4885 |
| US-20210128501-A1 | ANTIBACTERIAL COMPOUNDS | ARF1, ARL1, TLR1 | CDK1 1597/4885MEN1 1300/4885KMT2A 2533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.